However, of late, more selective PI3K inhibitors have been developed; this shift has occurred in response to the emerging role of class I isoforms in both tumor cell signaling and the tumor microenvironment, and a particular focus of our research in both contexts has been p110β. The gene discussed is PIK3CA; the disease is neoplasm.